Eledon Pharmaceuticals (ELDN) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eledon Pharmaceuticals is the larger company by market cap ($150.3 million vs $149.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELDN | RNA |
|---|---|---|
| Share price | $1.78 | $6.92 |
| Market cap | $150.34M | $149.27M |
| 1-day change | -6.32% | -0.86% |
| YTD return | +17.88% | — |
| 1-year return | +23.61% | — |
| 5-year return | -65.64% | — |
| EPS (TTM) | $-0.73 | $-5.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-45.62M | — |
| 52-week high | $4.49 | $16.77 |
| 52-week low | $1.39 | $6.36 |
| Distance from 52-week high | -60.36% | -58.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +405.62% | +217.92% |
| Average volume | 931.77K | 297.20K |
| Shares outstanding | 84.46M | 21.57M |
| Employees | 33 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
ELDN vs RNA FAQ
Which is bigger, Eledon Pharmaceuticals or Atrium Therapeutics?
Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $150.34M compared with $149.27M for Atrium Therapeutics (RNA).
Are Eledon Pharmaceuticals and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.